Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus


Following primary dengue virus (DENV) infection, non-structural protein 1 (NS1), a dengue-specific glycoprotein, is present in blood and is easily detected by various assays. However, for any infection thereafter (secondary infection), bioavailability of the glycoprotein greatly reduces sensitivity of DENV detection. Since secondary DENV infection is a risk factor for developing hemorrhagic fever, there is increasing need for more sensitive detection at this stage.

CDC investigators have developed a versatile method and monoclonal antibodies for detection of primary and secondary DENV infection. The antibodies specifically bind to heat-denatured NS1, allowing the addition of a heat denaturation step which greatly improves sensitivity of the detection assay. The assay was validated using actual dengue patient samples.

Potential Commercial Applications: Competitive Advantages:
  • Use of novel antibodies and methods for development of more sensitive diagnostics for primary and secondary DENV infection, including immunofluorescence assays, enzyme-linked immunosorbent assays, lateral flow assays and microsphere-based assay systems.
 
  • More sensitive DENV detection better for secondary infection.
  • Novel antibodies and methods can be applied to existing kits to increase sensitivity and ease of use.


Development Stage:
  • In vitro data available
  • Prototype


Related Invention(s):
E-148-2013/0


Inventors:

Elizabeth Hunsperger (CDC)  ➽ more inventions...

Tesfaye Taye (CDC)  ➽ more inventions...

Betty Poole-Smith (CDC)  ➽ more inventions...


Intellectual Property:
PCT Application No. PCT/US2015/036939
US Application No. 62/014,982


Publications:
Sharp TM, et al. PMID 24452132

Licensing Contact:
Tara Kirby, Ph.D.
Email: tara.kirby@nih.gov
Phone: 240-669-5128

OTT Reference No: E-182-2014/0
Updated: Apr 19, 2017